MedTrace Logo

Drug-drug Interaction (DDI) Rifabutin

NCT02138084 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2017-09-25

No results posted yet for this study

Summary

The purpose of this study is to provide dosing recommendations for the coadministration of BMS-663068 and Rifabutin with and without Ritonavir in upcoming Phase 3 studies and for prescribing information purposes

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

DRUG

BMS-663068

BMS-663068

DRUG

Rifabutin

Rifabutin

DRUG

Ritonavir

Ritonavir

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-14
Primary Completion
2014-07-24
Completion
2014-07-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02138084 on ClinicalTrials.gov